PEAR ANNOUNCES OHIO DEPARTMENT OF MENTAL HEALTH AND ADDICTION SERVICES WILL PROVIDE ACCESS TO PRESCRIPTION DIGITAL THERAPEUTICS TO HELP LOCAL COMMUNITIES CONTINUE FIGHT AGAINST OPIOID ADDICTION – Medical Alley Association

PEAR ANNOUNCES OHIO DEPARTMENT OF MENTAL HEALTH AND ADDICTION SERVICES WILL PROVIDE ACCESS TO PRESCRIPTION DIGITAL THERAPEUTICS TO HELP LOCAL COMMUNITIES CONTINUE FIGHT AGAINST OPIOID ADDICTION

Columbus, OH, Boston and San Francisco, April 22, 2021 – Pear Therapeutics, Inc. announced today that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-authorized prescription digital therapeutics (PDTs) reSET® and reSET-O® for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively. Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Ohio continue the fight against addiction. Funding is provided by the State Opioid Response (SOR) 2.0 grant, administered by OhioMHAS, and part of the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) SOR grant program for people in need of prevention, treatment and recovery support for opioid use disorder.

The Ohio SOR 2.0 grant comes at a time when many communities are seeing increased demand for behavioral health and recovery services amid the ongoing coronavirus pandemic. Pear was awarded a grant to provide reSET and reSET-O under the ‘Use of Innovation’ program that supports technology and innovation advancements in Ohio’s behavioral health care delivery system to support Ohioans on their recovery journeys. Ohio marks the third SOR grant awarded to Pear in 2021, with other SOR grants awarded by Indiana and Kentucky.

“While the pandemic has rightfully been front and center in everyone’s minds, the opioid epidemic hasn’t gone away – it persists as a threat to our citizens and our communities,” said OhioMHAS Director Lori Criss. “This funding will help partners like Pear Therapeutics connect even more Ohioans to treatment and recovery services and support their use of new technology and innovation to stem the tide of addiction.”

OhioMHAS will make reSET and reSET-O available to participating providers in a variety of outpatient treatment settings including opioid treatment programs that also administer transmucosal buprenorphine to prescribe and treat patients in the state of Ohio.

“Ohio has not lost sight of the need to help people suffering from substance use disorders during the pandemic. In line with Governor Dewine’s RecoveryOhio initiative, Pear is proud to work with OhioMHAS to fight the addiction crisis by providing Ohioans in recovery with access to evidence-based treatments through their mobile devices when and where they need it most,” said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics.

reSET and reSET-O have been tested in real-world use and randomized controlled trials, with results published in peer-reviewed medical journals1-5. Both products, which are adjunctive to outpatient counselling, provide patients with algorithm-driven cognitive behavioral therapy, fluency training, and contingency management, while clinicians receive access to clinical dashboards to inform in-office and tele visits. reSET is used as a monotherapy for patients 18 years of age or older with substance use disorder and reSET-O is used in combination with transmucosal buprenorphine for patients 18 years of age or older with opioid use disorder.

About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

About Prescription Digital Therapeutics (PDTs)
PDTs, such as Pear’s reSET-O digital treatment tool, are a new therapeutic class that uses software to directly treat disease. Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials demonstrating safety and effectiveness, evaluated and authorized by regulators like FDA, and used under the supervision of a prescribing clinician6,7. Unlike traditional medicines, PDTs are designed to collect real world data for use by prescribing clinicians and for population health management by payors and health systems. reSET-O has been tested in real world use and randomized controlled trials with results published in peer-reviewed medical journals.

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER